UK-headquartered start-up Tenpoint Therapeutics has reeled in a commendable $70 million in first-round financing that will be used to develop its cell-based therapies for sight-robbing diseases. The ...
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab. IL-13 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results